Article Data

  • Views 399
  • Dowloads 126

Original Research

Open Access

Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience

  • K. Karadayi1,2
  • C. Yildiz3
  • S. Karakus3,*,
  • O. Bozoklu Akkar3
  • G. Pakay Ugurlu3
  • A. Kurt1
  • A. Yanik3,4

1Departments of General Surgery, Cumhuriyet University School of Medicine, Sivas, Turkey

2Division of Surgical Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey

3Obstetrics and Gynecology, Cumhuriyet University School of Medicine, Sivas, Turkey

4Division of Gynecologic Oncology, Cumhuriyet University School of Medicine, Sivas, Turkey

DOI: 10.12892/ejgo2786.2016 Vol.37,Issue 2,April 2016 pp.194-198

Published: 10 April 2016

*Corresponding Author(s): S. Karakus E-mail: karakussavas@yahoo.com

Abstract

Introduction: The objective of this study was to assess the outcome of cytoreductive surgery (CRS) plus hyperthermic intraperitoneal chemotherapy (HIPEC) plus early postoperative intraperitoneal chemotherapy (EPIC) in patients with advanced gynecological malignancies. Materials and Methods: A retrospective series of 51 patients with advanced gynecologic cancer, evaluated between May 2008 to February 2014. Peritoneal Cancer Index (PCI) and Completeness of Cytoreduction (CCR) score were used in the study group. The study group consisted of the cancers of ovarian, fallopian tube, endometrial, and uterine sarcomas. Results: Mean PCI score of the study group was 18, and the postoperative complications were similar with the literature. Patients were followed in a period of 15 days to 64 months and the mean survival time was 22.8 months. Fifty-two percent of the patients were alive without evidence of the disease and overall one-year survival was found 56%. Conclusions: The authors concluded that CRS, HIPEC, EPIC, and peritonectomy are a crucial options in patients with advanced gynecological cancers.

Keywords

Cytoreductive surgery; HIPEC: EPIC; Peritonectomy.

Cite and Share

K. Karadayi,C. Yildiz,S. Karakus,O. Bozoklu Akkar,G. Pakay Ugurlu,A. Kurt,A. Yanik. Cytoreductive surgery and perioperative intraperitoneal chemotherapy for gynecological malignancies: a single center experience. European Journal of Gynaecological Oncology. 2016. 37(2);194-198.

References

[1] Königsrainer I., Horvath P., Struller F., Grischke E.M., Wallwiener D., Königsrainer A., Beckert S.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in recurrent epithelial ovarian cancer with peritoneal metastases: a single centre experience”. Langenbecks Arch. Surg., 2014, 399, 589.

[2] Robella M., Vaira M., Marsanic P., Mellano A., Borsano A., Cinquegrana A., et al.: “Treatment of peritoneal carcinomatosis from ovarian cancer by surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC)”. Minerva Chir., 2014, 69, 27.

[3] Abu-Zaid A., Azzam A.Z., AlOmar O., Salem H., Amin T., Al-Badawi I.A.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for managing peritoneal carcinomatosis from endometrial carcinoma: a single-center experience of 6 cases”. Ann. Saudi Med., 2014, 34, 159.

[4] Liu Y., Endo Y., Fujita T., Ishibashi H., Nishioka T., Canbay E., Li Y., Ogura S.I., Yonemura Y.: “Cytoreductive surgery under aminolevulinic acid-mediated photodynamic diagnosis plus hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinomatosis from ovarian cancer and primary peritoneal carcinoma: results of a phase I trial”. Ann. Surg. Oncol., 2014, 21, 4256. doi: 10.1245/s10434-014-3901-5. Epub 2014 Jul 24..

[5] Vizzielli G., Costantini B., Tortorella L., Petrillo M., Fanfani F., Chiantera V., et al.: “Influence of intraperitoneal dissemination assessed by laparoscopy on prognosis of advanced ovarian cancer: an exploratory analysis of a single-institution experience”. Ann. Surg. Oncol., 2014, 21, 3970. doi: 10.1245/s10434-014-3783-6. Epub 2014 May 22.

[6] Sugarbaker P.H.: “Peritonectomy procedures”. Ann. Surg., 1995, 221, 29.

[7] Cavaliere F., Giannarelli D., Valle M., Federici O., Liotta G., Perri P., et al.: Peritoneal carcinomatosis from ovarian epithelial primary: combined aggressive treatment”. In Vivo, 2009, 23, 441.

[8] Verwaal V.J., Bruin S., Boot H., van Slooten G., van Tinteren H.: “8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in pa-tients with peritoneal carcinomatosis of colorectal cancer”. Ann. Surg. Oncol., 2008, 15, 2426.

[9] Elias D., Lefevre J.H., Chevalier J., Brouquet A., Marchal F., Classe J. M., et al.: “Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin”. J. Clin Oncol 2009, 27, 681. doi: 10.1200/JCO.2008.19.7160. Epub 2008 Dec 22.

[10] Franko J., Ibrahim Z., Gusani N.J., Holtzman M.P., Bartlett D.L., Zeh H.J. 3rd.: “Cytoreductive surgery and hyperthermic intraperi-toneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis”. Cancer, 2010, 116, 3756.

[11] Chua T.C., Morris D.L., Saxena A., Esquivel J., Liauw W., Doerfer J., et al.: “Influence of modern systemic therapies as adjunct to cytoreduction and perioperative intraperitoneal chemotherapy for patients with colorectal peritoneal carcinomatosis: a multicenter study”. Ann. Surg. Oncol., 2011, 18, 1560.

[12] Sugarbaker P.H.: “Cytoreductive surgery and perioperative intraperitoneal chemotherapy for the treatment of advanced primary and recurrent ovarian cancer”. Curr. Opin. Obstet. Gynecol., 2009, 21, 15.

[13] Sugarbaker P.H.: “Cytoreductive surgery and perioperative intraperitoneal chemotherapy as a curative approach to pseudomyxoma peritonei syndrome”. Eur. J. Surg. Oncol., 2001, 27, 239.

[14] Jayne D.G., Fook S., Loi C.: “Peritoneal carcinomatosis from colorectal cancer”. Br. J. Surg., 2002, 89, 1545.

[15] Glehen O., Osinski D., Cotte E.: “Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures”. Ann. Surg. Oncol., 2003, 10, 863.

[16] Stephens A.D., Alderman R., Chang D.: “Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyper-thermic intraoperative itraperitoneal chemotherapy using the coliseum technique”. Ann. Surg. Oncol., 1999, 6, 790.

[17] Sugarbaker P.H.: “Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach”. Expert Opin. Pharmacother., 2009, 10, 1965.

[18] Begossi G., Gonzalez-Moreno S., Ortega-Perez G., Fon L.J., Sugarbaker P.H.: “Cytoreduction and intraperitoneal chemotherapy for the management of peritoneal carcinomatosis, sarcomatosis and mesothelioma”. Eur. J. Surg. Oncol., 2002, 28, 80.

[19] Feldman A.L., Libutti S.K., Pingpank J.F., Bartlett D.L., Beresnev T. H., Mavroukakis S.M., et al.: “Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy”. J. Clin. Oncol., 2003, 21, 4560.

[20] Yan T.D., Edwards G., Alderman R., Marquardt C.E., Sugarbaker P. H.: “Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma—a prospective study of 70 consecutive cases”. Ann. Surg. Oncol., 2007, 14, 515.

[21] Chua T.C., Yan T.D., Morris D.L.: “Outcomes of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal mesothelioma: the Australian experience”. J. Surg. Oncol., 2009, 99, 109.

[22] Young R.C., Perez C.A., Hoskins W.J.: “Cancer of the ovary”. In: De Vita V.T., Hellman S., Rosenberg S.A. (eds). Cancer: principles and practice of oncology. 4th ed. Philadelphia, Pa: Lippincott-Raven, 1993, 1226.

[23] Glehen O., Osinsky D., Cotte E., Kwiatkowski F., Freyer G., Isaac S., et al.: “Intraperitoneal chemohyperthermia using a closed abdominal procedure and cytoreductive surgery for the treatment of peritoneal carcinomatosis: morbidity and mortality analysis of 216 consecutive procedures”. Ann. Surg. Oncol., 2003, 10, 863.

[24] Karadayi K., Turan M., Karadayi S., Alagozlu H., Kilickap S., Buyukcelik A., et al.: “Cytoreductive surgery followed by hyperthermic intraperitoneal chemotherapy: morbidity and mortality analysis of our patients”. Turkiye klinikleri tip bilimleri dergisi, 2012, 32, 162.

[25] Baratti D., Kusamura S., Mingrone E., Balestra M.R., Laterza B., Deraco M.: “Identification of a subgroup of patients at highest risk for complications after surgical cytoreduction and hyperthermic intraperitoneal chemotherapy”. Ann. Surg., 2012, 256, 334.

[26] Karadayi K., Turan M., Sen M.: “A new technique for partial splenectomy with radiofrequency technology”. Surg. Laparosc. Endosc. Percutan. Tech., 2011, 21, 358.

[27] Griffiths C.T.: “Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma”. Natl. Cancer Inst. Monogr., 1975, 42, 101.

[28] Benoit L., Cheynel N., Ortega-Deballon P., Giacomo G.D., Chauffert B., Rat P.: “Closed hyperthermic intraperitoneal chemotherapy with open abdomen: a novel technique to reduce exposure of the sur-gical team to chemotherapy drugs”. Ann. Surg. Oncol., 2008, 15, 542.

[29] Plaisant N., Quenet F., Fabbro M., Gourgou S., Gutowski M., Saint Aubert B., Rouanet P.: “Secondary debulking surgery and intraperitoneal chemotherapy in advanced or recurrent epithelial ovarian cancer”. Gynecol. Obstet. Fertil., 2004, 32, 391.

[30] Piso P., Dahlke M.H., Loss M., Schlitt H.J.: “Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in peritoneal carcinomatosis from ovarian cancer”. World. J. Surg. Oncol., 2004, 2, 21.

[31] Ryu K.S., Kim J.H., Ko H.S., Kim J.W., Ahn W.S., Park Y.G., et al.: “Effects of intraperitoneal hyperthermic chemotherapy in ovarian cancer”. Gynecol. Oncol., 2004, 94, 325.

[32] Rufián S., Muñoz-Casares F.C., Briceño J., Díaz C.J., Rubio M.J., Ortega R., et al.: “Radical surgery, peritonectomy and intraoperative intraperitonealchemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer”. J. Surg. Oncol., 2006, 94, 316.


Abstracted / indexed in

Science Citation Index Expanded (SciSearch) Created as SCI in 1964, Science Citation Index Expanded now indexes over 9,500 of the world’s most impactful journals across 178 scientific disciplines. More than 53 million records and 1.18 billion cited references date back from 1900 to present.

Biological Abstracts Easily discover critical journal coverage of the life sciences with Biological Abstracts, produced by the Web of Science Group, with topics ranging from botany to microbiology to pharmacology. Including BIOSIS indexing and MeSH terms, specialized indexing in Biological Abstracts helps you to discover more accurate, context-sensitive results.

Google Scholar Google Scholar is a freely accessible web search engine that indexes the full text or metadata of scholarly literature across an array of publishing formats and disciplines.

JournalSeek Genamics JournalSeek is the largest completely categorized database of freely available journal information available on the internet. The database presently contains 39226 titles. Journal information includes the description (aims and scope), journal abbreviation, journal homepage link, subject category and ISSN.

Current Contents - Clinical Medicine Current Contents - Clinical Medicine provides easy access to complete tables of contents, abstracts, bibliographic information and all other significant items in recently published issues from over 1,000 leading journals in clinical medicine.

BIOSIS Previews BIOSIS Previews is an English-language, bibliographic database service, with abstracts and citation indexing. It is part of Clarivate Analytics Web of Science suite. BIOSIS Previews indexes data from 1926 to the present.

Journal Citation Reports/Science Edition Journal Citation Reports/Science Edition aims to evaluate a journal’s value from multiple perspectives including the journal impact factor, descriptive data about a journal’s open access content as well as contributing authors, and provide readers a transparent and publisher-neutral data & statistics information about the journal.

Submission Turnaround Time

Conferences

Top